-
Mashup Score: 0
No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Q&A: One-Year Efficacy, Safety of Risankizumab in Patients with Psoriatic Arthritis - 10 month(s) ago
In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
In this Q&A, Andrew Östör, MD, discussed the findings of a study that evaluated the one-year efficacy and safety of #risankizumab in patients with inadequate response/intolerance to biologics or conventional synthetic DMARDs. https://t.co/j0XtDYiSo7 https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Revolutionizing Rheumatology: Exploring the Impact of Telemedicine in Transforming Care - 10 month(s) ago
Although the benefits of telehealth are clear, it is not without its challenges. As the field of rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Although the benefits of #telehealth are clear, it is not without its challenges. As the field of #rheumatology moves into a post-pandemic world, the future of telemedicine hangs in the balance. Learn more: https://t.co/8zG4ypoNEC
-
-
Mashup Score: 0
At week 52, 58.5% of patients continuing risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
At week 52, 58.5% of patients continuing #risankizumab treatment and 55.7% of patients who switched to risankizumab at week 24 achieved ACR20. https://t.co/WOqbBAFH9e #PsoriaticArthritis https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Rheumatoid Arthritis Quiz: Clinically Suspect Arthralgia - 10 month(s) ago
Arthralgia is the precursor to rheumatoid arthritis for many patients. How much do you know about identifying patients with clinically suspect arthralgia? Test your knowledge with this quiz.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
ICYMI: Arthralgia is the precursor to #RheumatoidArthritis for many patients. How much do you know about identifying patients with clinically suspect arthralgia? Test your knowledge with this quiz. https://t.co/ygvWiCr9PM
-
-
Mashup Score: 0Rheumatoid Arthritis Quiz: Clinically Suspect Arthralgia - 10 month(s) ago
Arthralgia is the precursor to rheumatoid arthritis for many patients. How much do you know about identifying patients with clinically suspect arthralgia? Test your knowledge with this quiz.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Is the following statement true or false? The American College of #Rheumatology has identified 7 clinical parameters to define clinically suspect arthralgia. https://t.co/Z6rTyCadhO #RheumatoidArthritis
-
-
Mashup Score: 0Juliana Reed, MS: The Future of Biosimilar Access in the US - 10 month(s) ago
Juliana Reed, MS, predicts what the future holds regarding biosimilar access in the United States.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Juliana Reed, MS, predicts what the future holds regarding #biosimilar access in the United States. https://t.co/slxXE1VG8F #Adalimumab https://t.co/VGhnMtdbLY
-
-
Mashup Score: 0Juliana Reed, MS: Encouraging the Uptake of Biosimilars in the US - 10 month(s) ago
Juliana Reed, MS, explains the factors decision-makers need to consider to ensure lower-cost adalimumab biosimilars reach millions of patients in the United States.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Juliana Reed, MS, explains the factors decision-makers need to consider to ensure lower-cost #adalimumab #biosimilars reach millions of patients in the United States. https://t.co/QAm95yXPHv https://t.co/K1FtxoPagf
-
-
Mashup Score: 0Juliana Reed, MS: The Role of PBMs in US Adalimumab Biosimilars Launch - 10 month(s) ago
Although the recent launch of 7 adalimumab biosimilars should lead to cost savings and better access to medication, the role of pharmacy benefit managers raises concerns for Reed and her team.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Although the recent launch of 7 #adalimumab #biosimilars should lead to cost savings and better access to medication, the role of pharmacy benefit managers raises concerns for Reed and her team. https://t.co/r6fX8Ol9A7 https://t.co/K1FtxoOCqH
-
-
Mashup Score: 0Adam Dore, DO: Trends in the Treatment of Psoriatic Arthritis - 10 month(s) ago
Adam Dore, DO, discusses the recent developments in treating psoriatic arthritis and his predictions for the advancement of care in the upcoming year.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet-
Adam Dore, DO, discusses recent developments in the treatment of #PsoriaticArthritis and his predictions for advancing care in the upcoming year. https://t.co/NrFPDKIJn3
-
No statistically significant differences in retention rates were observed among those treated with #baricitinib monotherapy or in combination with methotrexate. https://t.co/beAn23M6c9 #RheumatoidArthritis